Global Pull Incentive Needed to Future-Proof Antibiotic Innovation, Says OHE Report

By HEOR Staff Writer

April 12, 2023

A new report highlights the pervasive market failure in the antibiotics space and proposes a globally aligned, value-based, fully-delinked pull incentive to future-proof antibiotic innovation. The mechanism would involve payers paying manufacturers a pre-specified subscription fee, based on the value of the antibiotic, over a pre-specified period, regardless of the volume of antibiotics used. The report suggests that the size of a global pull incentive should be calculated by aggregating revenue from all countries where the product is sold, with a 10-year ‘subscription’ type payment estimated to be $4.2 billion. Eligible products should be selected based on globally aligned criteria, including the unmet need to be addressed and a target product profile. Value assessment must be local, and its methodology must distinguish between higher and lower value products. The report concludes that investment in research is needed in the short term to develop communities of practice around economic modelling for antibiotics with a view to generating methods and finding evidence sources that will enable population benefits to be estimated using QALY-based modelling with appropriate adjustment for risk aversion.

Reference url

Recent Posts

Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics

By João L. Carapinha

October 27, 2025

Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...